Enfusion, Inc. (NYSE:ENFN) Shares Sold by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC lessened its holdings in shares of Enfusion, Inc. (NYSE:ENFN) by 32.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,233 shares of the company’s stock after selling 18,532 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in Enfusion were worth $394,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ENFN. KLP Kapitalforvaltning AS acquired a new position in shares of Enfusion during the fourth quarter worth $75,000. Dark Forest Capital Management LP purchased a new stake in Enfusion during the 4th quarter worth $128,000. Tower Research Capital LLC TRC lifted its holdings in Enfusion by 58.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock worth $136,000 after buying an additional 4,889 shares in the last quarter. Quantbot Technologies LP purchased a new position in Enfusion in the 4th quarter valued at about $144,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Enfusion during the fourth quarter valued at about $191,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Stock Up 0.5 %

Shares of NYSE ENFN opened at $10.85 on Monday. The stock’s 50 day moving average price is $11.06 and its two-hundred day moving average price is $10.50. Enfusion, Inc. has a 52-week low of $7.83 and a 52-week high of $11.80. The stock has a market capitalization of $1.40 billion, a P/E ratio of 271.29, a PEG ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. On average, analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current year.

Analysts Set New Price Targets

Separately, William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th.

Insider Buying and Selling

In other Enfusion news, CEO Oleg Movchan sold 2,790 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $11.48, for a total value of $32,029.20. Following the completion of the transaction, the chief executive officer now owns 643,299 shares in the company, valued at approximately $7,385,072.52. This represents a 0.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Neal Pawar sold 14,560 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $165,692.80. Following the completion of the sale, the chief operating officer now owns 1,217,067 shares in the company, valued at $13,850,222.46. The trade was a 1.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,223 shares of company stock worth $754,778 over the last quarter. 36.44% of the stock is owned by company insiders.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.